Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Study to Investigate the Efficacy and Safety of Solrikitug in Adults with Eosinophilic Esophagitis

99 years and younger
All genders
Solrikitug is a humanized immunoglobulin (Ig) G1 monoclonal antibody that binds to human thymic stromal lymphopoietin TSLP is an up-stream regulator of the T-helper 2 immune response and has been shown to drive the Th2 inflammatory responses that are involved in allergic inflammatory disorders, including eosinophilic esophagitis (EoE). This is …
Learn More

42847922MDD3003

99 years and younger
All genders
The study will investigate 20 mg seltorexant as adjunctive treatment to SSRI/SNRI antidepressants for major depressive disorder (MDD) compared with placebo as adjunctive therapy in patients with a partial response to first line antidepressant therapy.
Learn More

UPCC 11924: An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

99 years and younger
All genders
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or …
Learn More

High Tetraplegia Nerve Transfer

99 years and younger
All genders
Determine whether nerve transfer surgery in patients with high-cervical SCI will reinnervate paralyzed distal muscles, improve upper limb motor function, functional independence, and patient quality of life
Learn More

MUSCLE UP-PH

99 years and younger
All genders
PURPOSE This study will aim to (1) understand the way in which muscle loss occurs in Pulmonary Arterial Hypertension, particularly the role of fat surrounding the heart, and (2) look at the impact muscle loss has on quality of life, daily physical activity, and hospitalizations in patients with PAH. Subjects …
Learn More

AOC 1001-CS3 HARBOR

99 years and younger
All genders
This is a phase 3 trial of AOC 1001, an antibody-oligonucleotide conjugate. Protocol includes participants ages 16-65 with a clinical and genetic diagnosis of DM1 with DMPK CTG repeat length greater than or equal to 100; Penn site will enroll ages 18 to 65 years only. Participants will be randomized …
Learn More

UPCC 04522: Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)

99 years and younger
All genders
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines MK-4830 in combination with pembrolizumab in participants with PD-L1 positive NSCLC.
Learn More

UPCC 09924 An Open-label, Phase 1/2 Dose-Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants with KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

99 years and younger
All genders
Please refer to Protocol Section 3.1 (Study Objectives). Please refer to Protocol 3.2 (Study Endpoints). Please refer to Protocol 3.2 (Study Endpoints).
Learn More

Jazz EpiCom

99 years and younger
All genders
Please see section 3 of the protocol Please see section 3 of the protocol Please see section 3 of the protocol
Learn More

UPCC 13924: A Multicenter, Open-Label Phase 1/1B Dose-Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EPHA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors

99 years and younger
All genders
This is a first-in-human (FIH), open label Phase 1/1b study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate …
Learn More
811 - 820 of 930